The CART30 therapy, targeting CD30-positive Hodgkin's and Non-Hodgkin's lymphomas, represents a significant advancement in CAR T-cell therapy, particularly for patients with relapsed or refractory disease. The market for CAR T-cell therapies is expanding rapidly, with increasing demand for innovative treatments in hematological malignancies. Given the limited options for patients who have undergone autologous stem-cell transplantation or are refractory to standard therapies, CART30 could capture a substantial share of this niche market. Competitive analysis indicates that while several CAR T therapies are in development, the specificity for CD30 may provide a unique selling proposition. Diligence should focus on regulatory pathways, potential partnerships, and reimbursement strategies in the Chinese market and beyond.